It remains to be determined whether adding an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) to antiplatelet therapy has a therapeutic benefit on in-stent restenosis.
former stent costs over 50% more than the latter. The differentiated use of either or both devices may be recommended according to the anatomical, morphological, and historical (previous restenosis or none) features of the lesions and other factors (eg, duration of antiplatelet therapy) in patients, as well as taking into account the medical economics. Therefore, in addition to the application of a drug-eluting stent in appropriate lesions, the practical treatment options for reducing restenosis after PCI with a bare metal stent in combination with antiplatelet therapies also continue to increase.
Since angiotensin II promotes the proliferation of vascular smooth muscle cells, 1, 2) an angiotensin-converting enzyme (ACE) inhibitor was expected to reduce in-stent restenosis. However, the results of clinical trials remain controversial, yielding both positive and negative results. [3] [4] [5] [6] [7] [8] One of the reasons postulated for this is that angiotensin II is produced by pathways other than ACE, such as chymase in human vascular tissue.
9) The VAL-PREST trial documented the remarkable therapeutic effects of the angiotensin II type 1 (AT1) receptor blocker (ARB) valsartan on restenosis after stenting in complex coronary lesions. 10) In that trial, the ARB was more effective than placebo for preventing in-stent intimal proliferation, and its superiority over an ACE inhibitor can be predicted from the result that 68% of patients in the placebo group were taking an ACE inhibitor. Thus, the difference between the effectiveness of ARB and ACE inhibitors in preventing in-stent restenosis remains to be determined.
The aim of the present clinical trial was to assess whether an ARB or ACE inhibitor prevents in-stent restenosis by comparing CAD patients to a reference group taking neither agent. In contrast to the VAL-PREST trial, we used losartan instead of valsartan as the ARB, and cilostazol instead of ticlopidine as the antiplatelet medication.
METHODS
This clinical study was approved by the Ethics Committee of Fukushima Medical University and was carried out according to the Declaration of Helsinki. Nine institutes participated. Randomization of the subjects into the 3 treatment groups was performed by an independent for-profit study secretariat. Angiogram measurements and statistical analysis were conducted collectively by the authors in their department at Fukushima Medical University. Subjects: The baseline characteristics of the patients enrolled are shown in Table  I . The criteria used in this multicenter trial were: 1) subjects admitted to our hospital because of CAD; 2) instrumental evidence of myocardial ischemia by treadmill exercise ECG testing (ischemic ST depression of ≥ 1 mm) or by myocardial stress scintigraphy; 3) no previous history of coronary stenting; 4) either no pre- vious history of balloon angioplasty (n = 116) or only once (n = 12) (Table II) at the target lesion; and 5) angiographically documented significant stenosis (diameter stenosis of > 50%) in the epicardial coronary artery. The exclusion criteria were: 1) left main trunk lesions; 2) lesion length of ≥ 30 mm; 3) coronary bypass graft lesions; and 4) more than 2 previous balloon angioplasty procedures. Written informed consent was obtained from all subjects before PCI and after explaining the purpose and nature of the study. Registration: After registration, the study secretariat randomly divided the subjects into the 3 groups classified by the treatments described below. Treatment groups: Basal antiplatelet therapy with 162 mg aspirin twice daily (children's Bufferin 2 tablets/day) and 200 mg cilostazol twice daily was started in all subjects after registration. An ACE inhibitor (10 mg quinapril or 4 mg perindopril once a day: the ACE inhibitor group) or ARB (50 mg losartan once a day: the ARB group) was added to the basal antiplatelet drugs after stenting. The ACE inhibitors and ARB were not used in the basal treatment group. Nitrates, calcium antagonists, β-blockers and/or statins were used at the discretion of the attending physician. These treatments were continued for 6 months until followup angiography or an early endpoint within 6 months. Stenting procedure: The stents implanted were a GFX (Arterial Vascular Engineering Inc., Santa Rosa, CA, USA), or S670 or S660 (Medtronic AVE Inc., Minneapolis, MN, USA). Before the stent implantation procedure, all patients received an intravenous bolus administration of 150 IU/kg heparin to prevent thrombosis as well as intracoronary administration of 2.5 mg isosorbide dinitrate to prevent coronary arterial spasm. The implantation procedure was defined as successful when residual stenosis was less than 20%. If necessary, high-pressure postdilatation was performed with a noncompliant balloon. Endpoints: The endpoints of the study were an early revascularization procedure, and acute myocardial infarction or death within a follow-up period of 6 months. In-stent restenosis was defined as a luminal diameter stenosis of > 50% at follow-up angiography. In patients with restenosis, reintervention was performed in cases of typical angina and/or documented ischemia by exercise testing or myocardial stress scintigraphy. Assessment of coronary angiographic findings: Quantitative coronary angiography (QCA) was performed on off-line angiograms obtained just before stenting, immediately following stenting, and 6 months after stenting, using a computerassisted edge-detection system (QCA-CMS System, MEDIS Inc., Leiden, the Netherlands). With this analytical system, the coronary lumen diameter at the reference site (reference diameter, mm) and minimal lumen diameter (MLD, mm) were measured, and luminal diameter stenosis (diameter-stenosis, %) was calculated for each angiogram. The reference diameter was determined as the mean value of lumen diameters just proximal and distal to the stenotic site. We then calculated the acute gain (MLD just after stenting minus MLD before stenting, mm), late lumen loss (MLD just after stenting minus MLD at follow-up angiography, mm), and loss index (late lumen loss divided by acute gain). In addition, the stent/ artery ratio, ie, stent diameter divided by the reference diameter, was calculated in each case. Stent-edge restenosis was not considered to be restenosis in the present study.
11)
Baseline data collection: Smoking history was obtained by subject interviews. Diabetes mellitus was diagnosed by the 1999 criteria of the Japanese Diabetes Society. 12) Subjects with a history of antihypertensive therapy or with systolic blood pressure of ≥ 140 mmHg and/or diastolic pressure of ≥ 90 mmHg were defined as hypertensive. Hyperlipidemia was defined as one or more of total cholesterol of > 220 mg/dL, triglycerides of > 150 mg/dL, and/or LDL-cholesterol of > 140 mg/dL, which were calculated using the formula of Friedewald, et al.
13)
Determination of ACE D/I genotype: ACE gene polymorphism was analyzed in subjects who granted permission for gene analysis. DNA was extracted from venous blood, and the D/I polymorphism of the ACE gene was determined by polymerase chain reaction amplification of intron 16 of the ACE gene using primers. Statistical analysis: Results are expressed as the mean ± SD. Comparisons among quantitative data were performed by one-way ANOVA followed by Bonferroni's post-hoc test. Comparisons of incidence were tested using the chi-square test. A P value less than 0.05 was considered statistically significant.
RESULTS
After successful coronary stenting, 165 subjects were randomly assigned to 1 of the 3 treatment groups, ie, 56 subjects (57 lesions) to the basal group, 52 (53 lesions) to the ACE inhibitor group, and 57 (57 lesions) to the ARB group. One subject from the basal group died of coronary thrombosis 3 days after stenting, one from the basal group and another from the ARB group discontinued cilostazol due to palpitations, and ACE inhibitor administration was discontinued in 5 patients in the ACE inhibitor group because of dry cough. The clinical courses of these patients were not sufficiently followed by the independent for-profit study secretariat of this study. Of the 165 subjects, 126 with 128 lesions [42 (43 lesions) in the basal group, 42 (43 lesions) in the ACE inhibitor group, and 42 (42 lesions) in the ARB group] completed their treatment protocol and underwent follow-up coronary angiography. The remaining 31 patients did not agree to undergo the follow-up coronary angiography and were thus excluded from the study.
There were no differences in baseline systolic (144 ± 30, 142 ± 24, 147 ± 32
Vol 47 No 2 mmHg) or diastolic (76 ± 13, 75 ± 14 and 76 ± 15 mmHg) blood pressure or in heart rate just before starting treatment (71 ± 15, 73 ± 8, and 73 ± 14 beats/min) in the basal, ACE inhibitor, and ARB groups, respectively. Six months later, there were still no differences in systolic (138 ± 20, 138 ± 16, and 140 ± 22 mmHg) or diastolic (73 ± 9, 73 ± 10, and 73 ± 13 mmHg) blood pressure or in heart rate (74 ± 15, 71 ± 12, and 75 ± 12 beats/min), respectively, among the 3 groups. Baseline characteristics: Among the 3 groups, there were no significant differences in baseline subject basal characteristics, ie, age, gender, prevalence of smoking, hypertension, diabetes mellitus, hyperlipidemia, use of statins, acute coronary syndrome at study entry, and history of myocardial infarction. Likewise, no significant differences were observed in serum lipid and fasting blood sugar levels among the 3 groups (Table I) . Regarding baseline angiographic characteristics, there were no significant differences among the 3 groups in the location of treated lesions, prevalence of multivessel CAD, and de novo lesions or complex lesions [type B2 or C according to the modified American College of Cardiology/ American Heart Association classification (Table II) ].
14)
Stenting conditions: There were no differences in the stent diameter and length, ratio of the stent diameter to the reference diameter, or maximal inflation pressure of the balloon among the 3 groups (Table III) . There were no significant differences among parameters in basal (aspirin plus cilostazol), angiotensin-converting enzyme inhibitor (ACEI), and angiotensin II type 1 (AT 1 ) receptor blocker (ARB) groups. FBS indicates fasting blood sugar and MI, myocardial infarction.
Quantitative coronary angiography: No significant differences were observed in length of the lesion, its reference diameter, MLD, and diameter-stenosis before stent implantation among the 3 groups (Table IV) , nor were there any differences in MLD, diameter-stenosis, and acute gain immediately after stent implantation. At follow-up coronary angiography, the restenosis rate was slightly higher in the ACE inhibitor group than in the other 2 groups (χ 2 = 3.98, P = 0.13, Table V ). In the ACE group, the rate of target lesion revascularization in patients with restenosis was significantly higher (χ 2 = 7.25, P < 0.05, Table V) , while the diameterstenosis, late lumen loss, and loss index at 6 months after stent implantation were also significantly higher than in the basal treatment group (P < 0.05, Table IV ). ACE gene polymorphism: ACE gene polymorphism was examined in 75 subjects who gave approval for gene analysis. The ACE genotypes were as follows: homozygotes with two deletion alleles (DD), 8 (11%); heterozygotes with one deletion and one insertion allele (ID), 36 (48%); and homozygotes with two insertion alleles (II), 31 (41%). The genotypes were similarly distributed in the 3 treatment groups: DD/ID/II, 1/9/6 in the basal group, 4/12/14 in the ACE inhibitor group, and 3/15/11 in the ARB group. Among all subjects, there were no significant differences in the restenosis rate among the DD, ID, and II groups [0/8 (0%), 9/36 (25%), 6/31 (19%), respectively]. The target lesion revascularization rate, late lumen loss, and loss index also did not differ among the 3 genotype groups, ie, no restenosis was observed in subjects with DD genotype in all 3 groups. Furthermore, the restenosis rate did not differ significantly among the 3 groups in subjects with ID genotype (3/9 in the basal group, 4/12 in the ACE inhibitor group, and 2/15 in the ARB group, NS) nor in those with II genotype (1/ 6 in the basal group, 3/14 in the ACE inhibitor group, and 2/11 in the ARB group, NS).
DISCUSSION
The results of the present study can be summarized as follows. First, the restenosis rate of the basal treatment group was much lower than might be expected from previous studies. 15, 16) Second, no additive or synergistic effects of an ACE inhibitor or ARB on antiplatelet therapy with aspirin and cilostazol for prevention of in-stent restenosis were verified, while the ACE inhibitors were found to actually aggravate in-stent restenosis. The ACE genotype did not seem to affect the action of the ACE inhibitor or ARB on in-stent restenosis. These results suggest that the combination of an ACE inhibitor or ARB with aspirin and cilostazol may be ineffective for prevention of in-stent restenosis, and that an ACE inhibitor may in fact promote intimal proliferation after stent implantation.
Effect of basal antiplatelet treatment:
The restenosis rate at stenting sites ranged from 18 to 39% 10, [15] [16] [17] [18] [19] when treated with aspirin plus ticlopidine, versus a much lower 12% in the basal antiplatelet treatment group in this study. Ticlopidine has been established as one of the effective agents for antiplatelet therapy after stent implantation. 20, 21) On the other hand, cilostazol, an antiplatelet agent with a cyclic AMP-mediated vasodilating action, has also been used to induce an attenuation of in-stent restenosis. The effect of cilostazol was reported to be comparable 17) or even superior 18, 19) to that of ticlopidine on in-stent restenosis. Therefore, the preventive effect of cilostazol plus aspirin on in-stent restenosis might have contributed to the low restenosis rate in the basal group in this study.
The ratio of de novo lesions was slightly higher in patients in the basal group than in the ACE inhibitor and ARB groups (98%, 88%, and 86%: Table II) . Since the restenosis rate increases in lesions having previously undegone coronary intervention, 22) we can not exclude the possibility that it might have influenced the apparently low restenosis rate in the basal group. Effects of ACE inhibitor on in-stent restenosis: Among previous reports that assessed the effects of ACE inhibitors on in-stent restenosis, none confirmed their preventive effect angiographically, though one paper using intravascular ultrasound (IVUS) analysis showed that an ACE inhibitor attenuated reductions of the Vol 47 No 2 minimal lumen area and lumen volume at the stenting site. 23) In contrast, another study reported that ACE inhibitors worsened in-stent restenosis in patients with the DD genotype of ACE polymorphism. 7) Thus, it remains controversial whether ACE inhibitors reduce in-stent restenosis in clinical situations, though our results suggested that they may have exacerbated it, apparently irrespective of the type of ACE gene polymorphism. The precise mechanism(s) by which the ACE inhibitors promoted in-stent restenosis was beyond the scope of this study. There was no difference in parameters such as patient background, lesion length, reference diameter, or the sites of coronary stenotic lesions among our 3 subgroups. As a possible mechanism, an inherent property of ACE inhibitors may have been responsible, since the ARB did not worsen in-stent restenosis. It is also possible that ACE inhibitors actually promote tissue inflammation through the inhibition of kinin degradation. 7) An increase in tissue chymase activity is another possible mechanism. In human atherosclerotic tissue, the major angiotensin II-forming enzyme may be chymase rather than ACE.
9) It is known that the plasma angiotensin I concentration is increased by ACE inhibition as a positive feedback, so that ACE inhibitors may augment rather than reduce tissue angiotensin II accumulation by increasing plasma angiotensin I and tissue chymase.
Speculation may arise that there may have been slightly fewer cases of previous myocardial infarction in the ACE inhibitor group than in the basal and ARB groups (28%, 48%, and 41%, respectively: Table I ) which may have influenced the results of this study. In this regard, a large-scale report (stent implantation in 74% of subjects) showed that the presence of previous myocardial infarction was not a predictor of the risk of restenosis. 24) Thus, we assume that this speculation is unfounded. Effects of ARB on in-stent restenosis: The present study is the first to report the effect of ARB in combination with aspirin and cilostazol instead of ticlopidine, and it showed that, in contrast to the results of the VAL-PREST trial, no therapeutic benefit was detected from adding an ARB to the combination with aspirin and cilostazol. We have no clear explanation for this discrepancy with the VAL-PREST trial, which used an ARB or a placebo, ticlopidine, and aspirin. It would be difficult to simply compare the different results of these two clinical studies, since many factors such as patient population, race, types of stents, vessel size, and lesion morphology were so different. All subjects had a type B2/C complex lesion in the VAL-PREST trial, whereas only about half of our subjects had such a lesion. These different baseline characteristics of the patients may greatly affect the efficacy of an ARB. There is the further possibility that the considerably high anti-restenosis effect of aspirin plus cilostazol mentioned above may have masked the additional benefits of the ARB. Clinical implications: After the introduction of drug-eluting stents in mid-2004, their use in preventing in-stent restenosis became a standard PCI in Japan. Considering the high medical costs mentioned at the beginning of this paper, a strategy for differentiating the use of drug-eluting and conventional bare metal stents is necessary. In the meantime, therapeutic attempts to prevent in-stent restenosis as long as possible by using a bare metal stent in combination with antiplatelet therapy need to be continued. Although target lesion revascularization tended to be lower (NS) in the ARB group than in the basal group (Table V) , treatment with ARB showed no additional beneficial effects on protection against in-stent restenosis, since about half (49-56%) of the patients had complex lesions, as previously described. In contrast, in the VAL-PREST trial in which all patients had complex lesions of type B2 or C, the ARB was effective in preventing in-stent restenosis. Taken together, the beneficial effects of ARB plus antiplatelet therapy with aspirin and cilostazol or ticlopidine may be expected in cases of severe complex lesions, otherwise antiplatelet therapy alone without an ARB seems preferable. The findings of the present study also suggested the aggravating effects of an ACE inhibitor used strictly in combination with aspirin plus cilostazol. Although such a combination therapy was not effective when used for coronary stenotic lesions in this study, its efficacy for other diseases such as hypertension with arteriosclerosis obliterans was not clear, and should therefore be evaluated in further studies. Moreover, since the efficacy of an antiplatelet therapy remains insufficient for the prevention of in-stent restenosis, we must continue efforts to develop new therapies.
Systolic blood pressure 6 months after treatment with either an ACE inhibitor or ARB was not lowered significantly compared to that before treatment. Since there were no definitive trends in the blood pressure changes between the patients, we are unable to come up with an explanation. Conversely, this result may indicate that the differences in diameter stenosis and target lesion revascularization between the ACE inhibitor group and other 2 groups were not attributable to the possible influence of coronary perfusion pressures. Study limitations: There are several limitations in this clinical study. First, relatively small numbers of patients were enrolled, and a considerable number did not complete the study. Thus, a large-scale study is required to assess whether the combination of an ACE inhibitor with aspirin plus cilostazol is definitely ineffective against either type of coronary lesion or in-stent restenosis. Second, although our results may be applicable to Japanese subjects, they are inapplicable to other racial populations, given the distinct differences in ACE gene polymorphism among races. 25) Third, we did not assess the dose-related effects of pharmaceuticals, but used standard doses of ACE inhibitors and ARB for the treatment of hypertension. Therefore, we could not determine whether the dose of each agent used was optimal for achieving the intended therapeutic effects. In addition, we Vol 47 No 2 used either one of 2 agents, ie, quinapril or perindopril, for the ACE inhibitor group. The relative potencies of these 2 agents may have been different, although we employed the respective standard doses used in Japan. In regard to this issue, we do not know how ARBs other than losartan exert effects on in-stent restenosis. Fourth, in our study mean reference vessel diameters before stenting were 2.83-2.89 mm. We do not know whether and how our results may be modified if, for example, smaller vessels less than 2.8 mm in diameter, which have high rates of restenosis, are treated. 26 ) Fifth, we can not assess the possibility that patients who withdrew may have influenced the results if they had not been withdrawn. Sixth, an IVUS study 6 months after stent implantation may have been helpful to confirm whether the increased rate of target lesion revascularization in the ACE inhibitor group is due to intimal hyperplasia. 27 ) However, we did not perform an IVUS study. In addition, we do not know whether our observations for the ACE inhibitor group may have been influenced by a relatively weaker antiplatelet coagulation effect of cilostazol compared to ticlopidine 28) and a possible resultant difference in the effect of platelet-derived growth factor. Finally, we did not investigate the histopathological mechanisms of in-stent restenosis and its modification by the therapies. Considering these limitations, further study is required to achieve therapeutic advances in the attenuation of in-stent restenosis.
